文献速递医学教育与科研方法临床试验与 GCP

INVEST项目:调查证据合成在临床试验设计与分析中的应用

The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials.
PubMed 文献 · Trials · 2017-05-15

INVEST调查以2015年11月国际临床试验方法学会议约638名参会者为抽样框,106人(17%)完成问卷,其中半数为统计学家。受访者普遍支持在试验设计中描述既往证据、系统评价或Meta分析,但实际使用频率低于其认为应有的水平;最大障碍为时间限制及认为新试验是该领域首个试验。

要点

  • 受访者普遍支持在试验设计中使用既往证据、系统评价或Meta分析,但实际使用频率低于期望。
  • 仅50%(42/84)曾用Meta分析判断试验必要性,而74%(62/84)认为此举可取。
  • 最大感知障碍为时间限制,其次为认为新试验是该领域首个试验。

核心结论

  • 证据合成虽可能耗费资源,但其用于指导临床试验设计、实施与分析被广泛认为可取;作者倡导额外研究、培训与资源投入,以更高效地开展证据合成,长期有望节省成本。

研究设计与样本

  • INVEST调查以2015年11月国际临床试验方法学会议全部参会代表为抽样框,约638名参会者中106人(17%)完成问卷,其中半数为统计学家。

主要发现

  • 受访者对在试验设计中使用既往证据描述、系统评价或Meta分析的支持度普遍较高。
  • 仅50%(42/84相关受访者)曾用Meta分析判断试验是否必要,而74%(62/84)认为此举可取。
  • 仅6%(5/81相关受访者)曾用价值信息分析指导样本量计算,而22%(18/81)表示支持。
  • 79%(79/100)受访者认为应使用关于治疗效应的外部信息来指导分析相关方面。
  • 最大感知障碍为时间限制,其次为认为新试验是该领域首个试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When designing and analysing clinical trials, using previous relevant information, perhaps in the form of evidence syntheses, can reduce research waste. We conducted the INVEST (INVestigating the use of Evidence Synthesis in the design and analysis of clinical Trials) survey to summarise the current use of evidence synthesis in trial design and analysis, to capture opinions of trialists and methodologists on such use, and to understand any barriers. METHODS: Our sampling frame was all delegates attending the International Clinical Trials Methodology Conference in November 2015. Respondents were asked to indicate (1) their views on the use of evidence synthesis in trial design and analysis, (2) their own use during the past 10 years and (3) the three greatest barriers to use in practice. RESULTS: Of approximately 638 attendees of the conference, 106 (17%) completed the survey, half of whom were statisticians. Support was generally high for using a description of previous evidence, a systematic review or a meta-analysis in trial design. Generally, respondents did not seem to be using evidence syntheses as often as they felt they should. For example, only 50% (42/84 relevant respondents) had used a meta-analysis to inform whether a trial is needed compared with 74% (62/84) indicating that this is desirable. Only 6% (5/81 relevant respondents) had used a value of information analysis to inform sample size calculations versus 22% (18/81) indicating support for this. Surprisingly large numbers of participants indicated support for, and previous use of, evidence syntheses in trial analysis. For example, 79% (79/100) of respondents indicated that external information about the treatment effect should be used to inform aspects of the analysis. The greatest perceived barrier to using evidence synthesis methods in trial design or analysis was time constraints, followed by a belief that the new trial was the first in the area. CONCLUSIONS: Evidence syntheses can be resource-intensive, but their use in informing the design, conduct and analysis of clinical trials is widely considered desirable. We advocate additional research, training and investment in resources dedicated to ways in which evidence syntheses can be undertaken more efficiently, offering the potential for cost savings in the long term.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Clayton GL, Smith IL, Higgins JPT, et al. The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials. Trials. 2017. PMID: 28506284. doi:10.1186/s13063-017-1955-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。